What Is Mounjaro?

Mounjaro (tirzepatide) is a novel once-weekly injectable medication that is the first FDA-approved dual GIP/GLP-1 receptor agonist. Approved in May 2022 for type 2 diabetes, Mounjaro activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing superior glycemic control and weight reduction compared to GLP-1 agonists alone.

Formulation: Weekly subcutaneous injection (single-dose pen: 2.5, 5, 7.5, 10, 12.5, 15 mg)

Mechanism: GIP/GLP-1 dual receptor agonist

Manufacturer: Eli Lilly official patient site ↗

FDA Approved: 2022 — Key Trial: SURPASS-2 ↗ (ClinicalTrials.gov)

Who Is Mounjaro For?

FDA-Approved Indication: Type 2 diabetes management

Adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Mounjaro is particularly effective in T2D patients who need substantial HbA1c reduction and have metabolic obesity. Not FDA-labeled for obesity (Zepbound carries that indication), but frequently used off-label.

Eligibility criteria: BMI criterion not required; indicated for T2D management

Dosing & Titration Schedule

The standard titration protocol for Mounjaro (Tirzepatide) allows your body to adjust gradually to the medication, minimizing GI side effects. Each dose is typically maintained for 4 weeks before escalation, though your prescriber may modify this based on tolerability.

Dose	Approx. Weeks	Frequency	Phase
2.5 mg	Wk 1–4	Weekly	▶ Starting dose
5.0 mg	Wk 5–8	Weekly	→ Escalation
7.5 mg	Wk 9–12	Weekly	→ Escalation
10.0 mg	Wk 13–16	Weekly	→ Escalation
12.5 mg	Wk 17–20	Weekly	→ Escalation
15.0 mg	Wk 21–24	Weekly	★ Maintenance

Data source: FDA Prescribing Information for Mounjaro. Individual titration may vary based on tolerability and clinical response.

Weight Loss & Glycemic Outcomes

Clinical trial evidence (SURPASS-2): ~15–21% body weight in SURPASS trials (T2D); up to 22.5% in SURMOUNT-1 (obesity label/Zepbound)

These figures are based on clinical trial populations meeting specific inclusion criteria. Real-world results may differ due to adherence, diet, activity level, and individual biology. Calculate your projected weight loss →

Side Effect Profile

The most commonly reported side effects of Mounjaro are GI-related, typically most pronounced during dose escalation. They generally improve within 2–4 weeks at a stable dose.

•Nausea
•Diarrhea
•Vomiting
•Constipation
•Abdominal Pain
•Injection Site Reaction
•Fatigue

For detailed guidance on managing specific side effects, see the Tirzepatide side effects hub →

Cost Overview

Scenario	Estimated Monthly Cost
Cash pay (no insurance)	$1,000–$1,100/month
Commercial insurance	$25/month with Eli Lilly savings card for eligible commercially insured patients
Manufacturer savings program	Eli Lilly Mounjaro Savings Card — eligible commercially insured patients may pay as little as $25/month

Estimated based on Q1 2026 data. Prices vary by pharmacy, region, and insurance plan. Always verify current pricing with your pharmacy or plan.

Visit Eli Lilly’s savings program ↗ | Estimate your monthly cost →

Safety & Contraindications

Mounjaro carries a Boxed Warning regarding the risk of thyroid C-cell tumors (based on animal studies). The clinical relevance in humans is unknown, but the following contraindications apply:

Personal or family history of medullary thyroid carcinoma
MEN type 2 syndrome
Hypersensitivity to tirzepatide

Pregnancy: Mounjaro is not recommended during pregnancy. Discontinue at least 2 months before a planned pregnancy when possible. Discuss contraception and family planning with your prescriber.

Drug interactions: Delayed gastric emptying may affect oral medication absorption. Increased hypoglycemia risk with insulin or sulfonylureas.

How Does Mounjaro Compare to Other Options?

See all brand comparisons →

Frequently Asked Questions

What makes Mounjaro different from GLP-1 drugs like Ozempic?

Mounjaro is a dual GIP/GLP-1 receptor agonist — it activates both receptors simultaneously. GLP-1-only medications like Ozempic and Wegovy activate one receptor. The dual mechanism produces more robust weight loss and glycemic control in head-to-head trials.

How much weight can I lose on Mounjaro?

In SURPASS-2 (T2D), Mounjaro at 15 mg produced 11.2 kg (~24.7 lb) mean weight loss at 40 weeks. In the SURMOUNT-1 obesity trial, Zepbound (same molecule) produced 22.5% mean weight loss at 72 weeks — the highest ever seen for an approved anti-obesity medication.

Is Mounjaro the same as Zepbound?

Mounjaro and Zepbound both contain tirzepatide but have different FDA-approved indications. Mounjaro is labeled for type 2 diabetes; Zepbound is labeled for chronic weight management. They are the same molecule at the same doses.

What is the Mounjaro titration schedule?

Standard: 2.5 mg (weeks 1–4) → 5 mg (weeks 5–8) → 7.5 mg (optional) → 10 mg → 12.5 mg → 15 mg (max). Each step is maintained for ≥4 weeks. Dose escalation can be slowed based on tolerability.

Is Mounjaro covered by insurance for weight loss?

Mounjaro is labeled for T2D, so insurance coverage for the weight loss indication is inconsistent. For obesity-specific coverage, Zepbound (same drug) may have broader obesity-indication coverage depending on your plan.

What are the most common side effects of Mounjaro?

GI effects are most common: nausea (12–18%), diarrhea (12–17%), vomiting (6–9%), constipation (6–7%), abdominal pain (5–9%). These effects are typically highest during dose escalation and decrease with continued use.

Can Mounjaro cause low blood sugar?

Mounjaro alone has a low risk of hypoglycemia due to its glucose-dependent mechanism. However, hypoglycemia risk increases when combined with insulin or sulfonylureas. Dose reduction of those agents may be required.

Mounjaro: Complete Guide to Tirzepatide (2026)